Johnson & Johnson Inc. announced its formal bid for Crucell Tuesday, in a $2.4 billion deal that will see the pharmaceutical giant pick up the 82 percent of the Dutch vaccine-maker it does not already own.
The Am Law Daily reported on the deal in early October, when the specifics of the agreement were first announced. The two companies confirmed they were engaged in takeover negotiations in mid-September.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
